Retatrutide: The Next GLP-1? What We Know So Far

For the past couple of years, retatrutide has mostly lived in the "promising early data" category — Phase 2 numbers that looked impressive but hadn't yet been tested at the scale that actually gets a drug approved. That changed fast in the last several months. Eli Lilly's TRIUMPH and TRANSCEND Phase 3 programs have now delivered three major topline readouts, and the picture is no longer speculative. It's real trial data, in real patient populations, at registrational scale. What Retatrutide Is Retatrutide is a triple hormone receptor agonist — it acts on GLP-1, GIP, and glucagon receptors simultaneously. That third target, glucagon, is what separates it from tirzepatide (Mounjaro/Zepbound), which hits GLP-1 and GIP, and from semaglutide (Ozempic/Wegovy), which is GLP-1 only. More receptor targets isn't automatically better, but in retatrutide's case, it appears to be translating into larger effect sizes across the board. The Three Phase 3 Readouts So Far TRIUMPH-4 — Obesity with Knee Osteoarthritis (December 2025) This 68-week trial enrolled 445 adults with obesity or overweight and knee osteoarthritis, without diabetes. Both the 9 mg and 12 mg doses met all primary and key secondary endpoints. On the 12 mg dose, participants lost an average of 28.7% of body weight — a little over 70 pounds on average. Knee pain scores (measured on the WOMAC scale) dropped by roughly 76%, and more than one in eight participants reported being completely free of knee pain by the end of the trial, compared to about 4% on placebo. Cardiovascular risk markers — non-HDL cholesterol, triglycerides, systolic blood pressure — improved as well. TRANSCEND-T2D-1 — Type 2 Diabetes (March 2026) This 40-week trial targeted adults with type 2 diabetes not adequately controlled by diet and exercise alone. Retatrutide met the primary and all key secondary endpoints, delivering A1C reductions of up to 2.0% along with substantial weight loss — up to 16.8% of body weight on the highest dose. Notably, researchers reported no weight-loss plateau through the full 40 weeks, meaning participants were still losing weight when the trial ended rather than leveling off. TRIUMPH-1 — General Obesity (May 2026) The largest and most closely watched readout so far: 2,339 participants with obesity or overweight and at least one weight-related health condition, followed for 80 weeks. All three tested doses met the primary and key secondary endpoints. At the highest dose, average weight loss reached 25% of body weight, with the highest-BMI participants who escalated to maximum tolerated dose losing up to 30% over the full two-year trial arm. For comparison, tirzepatide's own pivotal SURMOUNT-1 trial showed roughly 22.5% weight loss over 72 weeks — meaning retatrutide's Phase 3 numbers are now running ahead of the drug that's currently considered the class leader. Side effects across all three trials followed the pattern typical of this drug class — GI-related events (nausea, digestive discomfort) were the most common, generally mild to moderate, and led to discontinuation in a minority of cases, with discontinuation rates rising somewhat at the highest dose. What's Still Coming Lilly has indicated seven additional Phase 3 readouts are expected before the end of 2026, covering additional populations including obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease. A head-to-head trial against an active comparator (rather than placebo) is also in progress, which will be the first data directly answering how retatrutide performs against existing GLP-1 therapies in the same study rather than across separate trials. Where This Actually Stands It's worth being precise about what this data does and doesn't mean. Retatrutide is not approved for any indication, anywhere, as of now. It remains an investigational compound — impressive Phase 3 results are a major step toward eventual approval, not the approval itself. The typical path from a positive topline readout to an FDA decision still involves full peer-reviewed publication, an official submission, and agency review, which realistically puts any approval decision at least many months out from these readouts, assuming the remaining trials continue to succeed. The Bottom Line Retatrutide has moved from theoretical "next GLP-1" speculation to a compound with genuine, large-scale Phase 3 evidence behind it — and so far, that evidence is showing larger weight loss than the current standard of care in matched trial designs. That's a meaningful scientific development. It is not, yet, a compound available through any approved prescription pathway, and the remaining months of 2026 will tell us a lot more about how it performs across the additional conditions still being studied.